ESG Report 2024

28 Environmental, Social and Governance Report 2024 The United Laboratories International Holdings Limited The Group consistently adheres to the mission of providing safe and effective products to patients worldwide, while actively participating in various chamber and association activities to promote industry development and communication. Currently, we serve as an executive director unit of the China Chamber of Commerce for Import & Export of Medicines & Health Products (referred to as "CCCMHPIE"), assisting the chamber in promoting pharmaceutical trade and investment, serving as a bridge between government and enterprises, connecting domestic and international markets to promote the globalisation of China's pharmaceutical and healthcare industry. Furthermore, the Group is also a member of the China Pharmaceutical Industry Association, contributing to the development and communication within the chemical pharmaceutical sector. Through these platforms, we are able to share knowledge and experience with industry professionals, jointly driving progress in the pharmaceutical and healthcare industry, and committing to improving patient access to safe and effective products. 6.2.1 Domestic Market The Group is primarily engaged in the research, development, production, and sales of APIs and intermediates, finished products, veterinary drugs, pharmaceutical capsules and medical devices. As one of the leading comprehensive pharmaceutical companies in China, the Group's product portfolio includes human pharmaceuticals and animal healthcare. The Group has a well-established sales team for intermediates, APIs, and formulations, with a sales network covering all over China. 6.2.2 Global Market Overseas Certifications 39 cases Overseas Registrations 81 cases Overseas Business Revenue 2 64. RMB billion The Group actively expands its international business, enhancing its global industrial layout and export operations. During the Year, the Group generated RMB2 64 billion in overseas business revenue, accounting for 19.2% of the Group's total revenue. Currently, the Group's international business covers intermediates and APIs, with a sales network spanning major pharmaceutical markets and emerging markets worldwide, including China, Europe, India, the Middle East, South America, and Africa. It holds a leading position in the upstream industry of penicillin antibiotics globally. The Group's intermediates and APIs have obtained official certifications from multiple countries, such as the European Union Certification of suitability of European Pharmacopoeia monographs (CEP), the United States FDA, Germany, India, Japan, Brazil, and Mexico. Currently, the Group has a total of 39 overseas certifications and 81 overseas registrations. . Finished products covering over Business Progress in Domestic Market Intermediates & APIs serving Animal healthcare serving customers 200 customers 300+ Health and community clinics 330,000 Hospitals 23,000 Pharmacies 230,000